TL;DR
- 1.IGFBP-3 binds roughly 80 percent of your circulating IGF-1 and holds it inactive. If your IGFBP-3 is low, your actual free IGF-1 exposure runs higher than your total IGF-1 lab result shows.
- 2.A 2023 study in the Journal of Clinical Endocrinology and Metabolism found the IGF-1:IGFBP-3 molar ratio diagnosed growth hormone deficiency with 87.5 percent sensitivity. IGF-1 alone managed only 42.2 percent.
- 3.All major GH peptides raise both IGF-1 and IGFBP-3, but not always in proportion. MK-677 tends to raise both in lockstep. Pulsatile stacks like ipamorelin may see IGF-1 rise faster than IGFBP-3 in the early weeks.
- 4.Insulin resistance, liver stress, and genetics each suppress IGFBP-3 independently of your peptide protocol. Improving insulin sensitivity can raise your ratio without touching your dose.
- 5.The IGFBP3 rs2854744 polymorphism directly controls your baseline IGFBP-3 level. C/C genotype carriers run lower IGFBP-3 than A/A carriers, meaning the same protocol delivers more free IGF-1 to their tissues.
IGFBP-3 is the protein that binds roughly 80 percent of your circulating IGF-1 and holds it in an inactive form until your tissues signal that they need it. Most peptide users have never had it tested. That means most people on GH protocols are reading only half the picture when they look at their bloodwork.
The share of circulating IGF-1 that IGFBP-3 holds in bound, inactive form. The remaining 20 percent is the free IGF-1 fraction that actually reaches your tissues and drives downstream signaling.
Total IGF-1 is a useful number. But it tells you the size of the tank, not how much of it is flowing. If your IGFBP-3 is low -- because of insulin resistance, liver stress, or a genetic variant that reduces its baseline expression -- more of that tank is running free at all times. The amount of IGF-1 reaching your tissues can be substantially higher than the lab result implies.
Here is the metric that captures this: the IGF-1:IGFBP-3 molar ratio. It is not standard in most peptide monitoring protocols. The Endocrine Society's 2011 Clinical Practice Guideline on Adult Growth Hormone Deficiency (Molitch, Clemmons et al., Journal of Clinical Endocrinology and Metabolism) specifies IGF-1 as the sole biochemical marker for GH monitoring in adults. IGFBP-3 is not in the protocol. But that guideline was written for GH-deficient patients on prescription GH therapy, not for healthy adults running pulsatile peptide stacks. The research on the ratio has moved significantly further since 2011, and it tells a different story.
In plain English: Think of IGF-1 as water and IGFBP-3 as a sponge. Total IGF-1 is the total water in the system. Free IGF-1 is the water already dripping out of the sponge and running loose. A small sponge holds less water back than a large one -- even if the total water is the same. Testing only total IGF-1 tells you how much water there is. Testing the ratio tells you how much is dripping onto your tissues right now.
Why the IGF-1:IGFBP-3 Ratio Outperforms Total IGF-1 Alone
The strongest recent evidence for the ratio comes from a 2023 study in the Journal of Clinical Endocrinology and Metabolism by Haj-Ahmad and Mahmoud et al. The team tested the diagnostic performance of individual biomarkers against the molar ratio in children with growth hormone deficiency. The result was striking: the molar ratio achieved 87.5 percent sensitivity for GHD diagnosis. IGF-1 alone managed only 42.2 percent. When all three markers were combined (IGF-1, IGFBP-3, and the ratio), specificity reached 97.7 percent.
"The serum IGF-1 to IGFBP-3 molar ratio demonstrated superior diagnostic performance over either marker alone, achieving 87.5% sensitivity and 83.0% specificity for growth hormone deficiency diagnosis -- compared with 42.2% sensitivity for IGF-1 measured in isolation."
Haj-Ahmad M et al., Journal of Clinical Endocrinology and Metabolism, 2023
The ratio does not just diagnose deficiency better. It also predicts risk on the high end. A 2023 EPIC-Heidelberg cohort analysis (Mukama T et al., Journal of Clinical Endocrinology and Metabolism) following more than 25,000 participants over 17.5 years found that higher IGF-1 was independently associated with breast cancer (HR 1.25) and prostate cancer (HR 1.31). The epidemiological risk accumulated disproportionately in individuals where IGF-1 was high relative to IGFBP-3. That is exactly what a skewed molar ratio captures.
For the peptide user running a GH secretagogue protocol, the direction of concern is different from GHD -- you are intentionally elevating the GH axis, not correcting a deficiency. But the core principle is identical: total IGF-1 without IGFBP-3 leaves half the picture dark, on both the low end and the high end.
How to Calculate Your IGF-1:IGFBP-3 Molar Ratio
The calculation requires a unit conversion because labs report the two proteins differently. Most US labs report IGF-1 in ng/mL and IGFBP-3 in ng/mL or ug/mL. The molecular weights are different (7.6 kDa for IGF-1 vs 28.7 kDa for IGFBP-3), so you convert both to nanomoles per liter before dividing.
Molar ratio = [IGF-1 (ng/mL) x 0.13] divided by [IGFBP-3 (ng/mL) x 0.035]
If your lab reports IGFBP-3 in ug/mL or mg/L (these are identical units: 1 mg/L = 1 ug/mL = 1,000 ng/mL), multiply the IGFBP-3 number by 1,000 first to get ng/mL, then apply the formula above.
| Scenario | IGF-1 (ng/mL) | IGFBP-3 (ng/mL) | Molar Ratio | Interpretation |
|---|---|---|---|---|
| Normal adult baseline | 175 | 3,400 | 0.19 | IGFBP-3 comfortably buffers IGF-1. Free IGF-1 fraction is proportionate to total. |
| Protocol running well | 280 | 4,200 | 0.25 | Both markers elevated together. Ratio within expected range for intentional GH axis activation. |
| IGFBP-3 suppressed (same IGF-1) | 280 | 2,200 | 0.47 | Same total IGF-1 as row above, but significantly less buffering. Free IGF-1 fraction substantially higher. |
| IGF-1 outrunning IGFBP-3 | 380 | 3,000 | 0.47 | IGF-1 is rising faster than the binding system. Evaluate insulin status and cycle length. |
| GH axis suppressed | 75 | 1,800 | 0.12 | Both low. Consistent with GH deficiency or testing too early in the protocol before steady state. |
The worked example in row 3 is the one most peptide users miss. Two people with IGF-1 of 280 ng/mL look identical on a standard lab panel. But if one has IGFBP-3 of 4,200 ng/mL and the other has 2,200 ng/mL, their free IGF-1 tissue exposure is dramatically different. The first person has robust buffering. The second is running a significantly higher functional IGF-1 load -- the tissues see more, even though the total number is exactly the same.
How Different GH Peptides Change the Ratio
Not all GH peptides affect the ratio the same way. The key variable is whether the compound drives continuous IGF-1 elevation or pulsatile GH release. Continuous elevation tends to raise IGFBP-3 in parallel because the liver has sustained time to upregulate both outputs. Pulsatile protocols may see IGF-1 rise faster than IGFBP-3 during the early weeks of a cycle.
MK-677 (Ibutamoren)
The 1996 Chapman et al. trial in the Journal of Clinical Endocrinology and Metabolism showed IGF-1 rising from 141 to 265 ug/L over four weeks of continuous oral 25 mg/day dosing, with IGFBP-3 rising significantly alongside it. Continuous ghrelin-receptor activation drives the hepatic GH signal long enough to upregulate both markers proportionately. The ratio tends to stay stable on MK-677 unless insulin sensitivity degrades as the protocol extends. The glucose effect documented in the Nass et al. two-year trial can suppress IGFBP-3 over time by raising insulin, which then feeds back to inhibit hepatic IGFBP-3 secretion. See the MK-677 long-term results guide for the two-year picture. For the current regulatory standing and sourcing context, visit the MK-677 peptide page.
CJC-1295 (GHRH analog)
The 2006 Teichman et al. JCEM Phase 1/2 trial showed CJC-1295 with DAC elevated IGF-1 by 1.5 to 3-fold for 9 to 11 days per weekly injection, with confirmed IGFBP-3 increases as part of the broader GH axis response. Sustained GHRH priming from DAC appears to drive hepatic IGFBP-3 output alongside IGF-1 -- which is why the CJC-ipamorelin stack, when working properly, tends to produce co-elevation of both markers rather than a widened ratio. Test at trough (mid-week between injections for weekly DAC dosing) to capture a stable plateau rather than a post-injection peak.
GHRP-2 and Ipamorelin
The 2004 Bowers et al. JCEM study of 30-day continuous subcutaneous GHRP-2 infusion in older adults showed IGF-1 rising to a stable elevated plateau, with IGFBP-3 increasing measurably by days 14 and 30. Ipamorelin -- the cleaner, lower-cortisol GHRP -- has not completed published RCTs measuring the molar ratio specifically. The expected behavior mirrors GHRP-2 on a pulsatile daily schedule: IGF-1 rises in the early weeks while IGFBP-3 catches up over weeks 4 to 6. If ipamorelin is not producing any IGF-1 response at all, the bottleneck may be at the GHSR receptor itself. The GHSR non-responder guide covers that scenario in detail.
The practical implication: if you are four weeks into a pulsatile stack and your molar ratio looks elevated, do not immediately conclude the protocol is dangerous. Your IGFBP-3 may still be catching up to the IGF-1 elevation. Test again at week 8 and track the direction. If the ratio is still elevated or rising at eight weeks with IGF-1 stable, IGFBP-3 is not keeping pace -- that is the signal to investigate why before extending the cycle.
The sensitivity of total IGF-1 alone for detecting GH axis dysfunction in the 2023 JCEM study. The molar ratio nearly doubled it to 87.5%. The metric most peptide users monitor is the less informative of the two.
Three Reasons Your IGFBP-3 Can Be Suppressed Before You Start Any Protocol
This is the part that surprises most people. Your IGFBP-3 is not just a reflection of your GH axis. It is regulated by insulin, liver function, and a genetic variant that sets your baseline production level independently of everything else. All three can suppress it before you inject your first dose of anything.
1. Insulin resistance suppresses IGFBP-3 at the liver
Chronically elevated insulin directly inhibits hepatic IGFBP-3 secretion. This is a well-documented pathway: insulin promotes free IGF-1 availability by reducing its carrier protein. If you have metabolic syndrome, central adiposity, or prediabetes, your IGFBP-3 may already be running low at baseline regardless of your peptide status. Starting a GH secretagogue on top of already-suppressed IGFBP-3 amplifies your free IGF-1 exposure beyond what any total IGF-1 test will show. Improving insulin sensitivity -- through carbohydrate management, exercise, or GLP-1 support -- can raise your IGFBP-3 and improve your ratio without changing your peptide dose at all.
2. Liver stress reduces hepatic IGFBP-3 output
IGFBP-3 is synthesized primarily in the liver. Hepatic stress from alcohol, non-alcoholic fatty liver disease (NAFLD), or elevated AST/ALT can reduce IGFBP-3 output independent of the GH axis. A June 2026 review in Frontiers in Endocrinology by Dominikowski et al. surveying the current evidence base for GH-IGF1 axis peptides explicitly identified "chronic IGF-1 elevation" as a "unifying class effect" across GH secretagogue categories, flagging the absence of long-term safety data in off-label users. If your IGFBP-3 is low while your liver enzymes are trending up, that combination warrants a recheck of both markers before extending any long cycle.
3. The IGFBP3 rs2854744 variant sets your genetic floor
The A-202C promoter polymorphism in the IGFBP3 gene directly controls baseline IGFBP-3 expression level. A 2001 study by Deal, Ma et al. in the Journal of Clinical Endocrinology and Metabolism established the genotype gradient clearly: A/A carriers have the highest baseline IGFBP-3 production, A/C carriers intermediate, and C/C carriers the lowest. This is a constitutional difference -- it does not change based on protocol or diet. If you carry C/C at this position, your baseline ratio will lean elevated compared to someone with the same total IGF-1 who carries A/A. The same protocol delivers meaningfully more free IGF-1 to the C/C genotype. For more on how your IGF-1 receptor genetics compound this, see the IGF-1 receptor genetics guide.
What a Skewed Ratio Actually Signals and What to Do About It
There is an important distinction between a ratio that is temporarily elevated because your IGFBP-3 has not fully caught up to a new protocol, and a ratio that is chronically elevated because IGFBP-3 is structurally suppressed. The response is different in each case.
If your ratio is elevated at weeks 3 to 4 of a new pulsatile protocol (ipamorelin, CJC-1295 without DAC, sermorelin), retest at week 8. If the ratio has normalized by then, IGFBP-3 caught up. If the ratio is still elevated or rising at eight weeks, the IGFBP-3 is not responding proportionately. That is your signal to check fasting insulin and liver enzymes before extending. The IGF-1 blood test timing guide covers the compound-specific draw windows so you are comparing apples to apples between tests.
If your ratio is elevated before you start any protocol, the driver is metabolic or genetic. Run fasting insulin and HbA1c before starting any GH secretagogue. If fasting insulin is above 10 uIU/mL, address insulin sensitivity first. That intervention alone can raise IGFBP-3 and reduce your baseline free IGF-1 load -- so that when you do start a protocol, the ratio stays in a proportionate range rather than immediately running hot.
If your ratio is normal but IGF-1 is high in absolute terms, IGFBP-3 is keeping up. Both markers are elevated together proportionately. This reflects a functioning GH axis -- it is what a working GH secretagogue protocol is supposed to do. The next question is whether the absolute IGF-1 ceiling warrants a dose adjustment, which is a separate analysis. The GHR Exon 3 d3/d3 genotype is the most common reason someone's IGF-1 runs high on a standard dose -- those carriers convert GH pulses to IGF-1 more efficiently than average. The GHR Exon 3 deletion guide covers the d3 pharmacogenomics in detail.
A 2025 study in Frontiers in Endocrinology (Zhao et al., 588 participants) confirmed that higher IGFBP-3 was associated with 62 percent lower odds of metabolic abnormality, independent of age. High absolute IGFBP-3 is not a concern -- it is protective. The concern is when IGFBP-3 fails to rise proportionately with IGF-1, leaving excess free IGF-1 circulating without its primary buffer intact.
| What you see on labs | Most likely meaning | Recommended next step |
|---|---|---|
| High ratio, IGF-1 elevated, IGFBP-3 low | Free IGF-1 excess. IGFBP-3 not buffering the IGF-1 elevation. | Check fasting insulin, liver enzymes, IGFBP3 genotype. Consider reducing dose or shortening cycle. |
| Normal ratio, both markers elevated | Protocol working. GH axis activated proportionately. | Monitor at steady state. Absolute IGF-1 ceiling is the next variable to assess. |
| Low ratio, both markers low | GH axis not fully activated. Too early in protocol or compound not working. | Retest at weeks 4 to 6. Rule out GHSR non-responder status if still flat at week 8. |
| Elevated ratio at pre-protocol baseline | Structurally low IGFBP-3. Insulin resistance or IGFBP3 C/C genotype likely. | Address insulin sensitivity before starting. Retest IGFBP-3 after 8 to 12 weeks of metabolic intervention. |
Verdict: Test IGFBP-3 alongside IGF-1 on every GH peptide cycle, starting at baseline. The ratio between the two tells you something neither marker can show alone: how much IGF-1 is actually reaching your tissues in free, bioactive form. If the ratio is elevated because IGFBP-3 is suppressed by insulin resistance, that is a metabolic problem you can fix before it becomes a protocol problem. If it is a genetic variant at IGFBP3 rs2854744, you need to know it is there before you stack protocols that drive IGF-1 further up. Upload your raw DNA file to see your IGFBP3 genotype, your GHR Exon 3 status, and the full panel of variables that determine how your tissues respond to GH axis peptides. Or order a saliva kit if you are starting from scratch.
Your DNA shapes how you respond to the peptides discussed above.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
What is the normal IGF-1 to IGFBP-3 molar ratio?
In healthy adults, the molar ratio typically falls between 0.15 and 0.30. A ratio above 0.40 suggests IGFBP-3 is no longer fully buffering the circulating IGF-1, meaning a higher fraction of free IGF-1 is reaching tissues. Calculate your own using: [IGF-1 (ng/mL) x 0.13] divided by [IGFBP-3 (ng/mL) x 0.035]. If your lab reports IGFBP-3 in mg/L or ug/mL, multiply by 1,000 first to convert to ng/mL.
Why is my IGF-1 high but my IGFBP-3 is normal or low?
This pattern means your GH axis is generating more IGF-1 than the binding protein system is upregulating in response. This can happen in the early weeks of a pulsatile protocol before IGFBP-3 catches up, or it can reflect structurally suppressed IGFBP-3 from insulin resistance, liver stress, or the IGFBP3 C/C genotype. Retest at eight weeks of steady use. If IGFBP-3 is still flat and IGF-1 remains elevated, check fasting insulin and liver enzymes before continuing.
Does IGFBP-3 increase with growth hormone peptides?
Yes, when GH peptides are working through the full GH-liver axis, both IGF-1 and IGFBP-3 should rise. A 1996 JCEM trial on MK-677 showed both markers rising significantly within four weeks. A 2006 JCEM trial on CJC-1295 confirmed IGFBP-3 elevation alongside IGF-1. However, IGFBP-3 tends to lag behind IGF-1 in the early weeks of a pulsatile protocol. Always test at steady state (weeks 4 to 6) before concluding IGFBP-3 is not responding.
How do I lower my IGF-1 to IGFBP-3 ratio?
There are two levers: reduce IGF-1 (lower dose, shorter cycle, switch to a weaker compound) or raise IGFBP-3 (improve insulin sensitivity, reduce liver stress, or allow more time for IGFBP-3 to catch up after starting a protocol). Improving insulin sensitivity through exercise, carbohydrate management, or GLP-1 support is often the fastest way to raise IGFBP-3 without changing your peptide dose at all.
What is the difference between total IGF-1 and free IGF-1?
Total IGF-1 is the sum of all IGF-1 in your blood, both the portion bound to carrier proteins like IGFBP-3 and the small free fraction. About 80 percent is bound and biologically inactive; the remaining 20 percent is free and reaches receptors in your tissues. Total IGF-1 is what standard labs measure. Free IGF-1 tests exist but are expensive and not widely standardized. The molar ratio is the practical proxy for estimating how much of your total IGF-1 is running in free form.
Should I test IGFBP-3 on every GH peptide cycle?
At minimum, test IGFBP-3 once at baseline before starting a GH secretagogue, and once again at four to six weeks of steady protocol use. If the ratio is elevated at baseline, investigate insulin sensitivity before proceeding. If the ratio is elevated at the steady-state check and IGFBP-3 has not risen with IGF-1, check metabolic and hepatic markers before extending the cycle. Two draws per cycle gives you the actionable information without unnecessary testing.
Can a skewed IGF-1:IGFBP-3 ratio increase long-term health risk?
The epidemiological association between elevated free IGF-1 and certain cancers is strongest when IGFBP-3 is disproportionately low relative to IGF-1, not when both are elevated together. A 2023 EPIC-Heidelberg cohort study found that high IGF-1 was associated with elevated breast and prostate cancer hazard ratios over 17.5 years, with the risk concentrated in individuals where IGF-1 was high relative to binding protein levels. This is a long-term population-level signal, not an acute risk from a single short cycle. It is, however, a strong argument for monitoring the ratio over extended protocol use rather than relying on total IGF-1 alone.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.